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CLINICAL INVESTIGATION
State Variability in the Prevalence and Healthcare Utilization
of Assisted Living Residents with Dementia
Kali S. Thomas, PhD,* Wenhan Zhang, MPH,† Portia Y. Cornell, PhD,* Lindsey Smith, MPP,‡
Brian Kaskie, PhD,§ and Paula C. Carder, PhD‡
OBJECTIVES: Almost 1 million older and disabled adults
who require long-term care reside in assisted living (AL),
approximately 40% of whom have a diagnosis of Alzheimer’s
disease and related dementias (ADRD). States vary in their reg-
ulations specific to dementia care that may influence the pres-
ence of residents with ADRD in AL and their outcomes. The
objectives of this study were to describe the state variability in
the prevalence of ADRD among Medicare beneficiaries resid-
ing in larger (25+ bed) ALs and their healthcare utilization.
DESIGN: Retrospective observational national study.
PARTICIPANTS: National cohort of 293,336 Medicare
fee-for-service enrollees residing in larger (25+ bed) ALs in
2016 and 2017 including 88,867 (30.3%) residents with
ADRD. We compared this cohort’s characteristics and
healthcare utilization with that of individuals with ADRD
who resided in nursing homes (NHs; n = 602,521) and the
community (n = 2,074,420).
METHODS: Medicare enrollment data, claims, and the NH
Minimum Data Set were used to describe differences among
ADRD patients in AL, NHs, and the community. We present
rates of NH admission and hospitalization, by state, adjusting
for age, sex, race, dual eligibility, and chronic conditions.
RESULTS: The prevalence of ADRD among AL residents
varied by state, ranging from 24% to 47%. In 2017, AL resi-
dents with ADRD had higher rates of NH admission than
their community-dwelling counterparts (adjusted national
average = 24%, ranging from 14% to 35% among states).
AL residents with ADRD had higher rates of hospitalization
(38%) than populations in either NHs (29%) or the commu-
nity (34%), and ranged from 29% to 45% of residents
among states.
CONCLUSION: These findings have implications for states
as they regulate AL and for healthcare professionals whose
patients reside in AL. Future work is needed to understand
specific elements of states’ regulatory environments and local
markets that may impact access and outcomes for this vulner-
able population of residents with ADRD. J Am Geriatr Soc
68:1504-1511, 2020.
Keywords: assisted living; Alzheimer’s disease and
related dementias; long-term care
Over the past 2 decades, assisted living (AL) has rapidlyemerged as a preferred residence for many older and
disabled adults who require long-term care. Each day in
2016, approximately 29,000 AL residences were home to
more than 800,000 people.1 Studies vary on their preva-
lence estimates of cognitive impairment or an Alzheimer’s
disease and related dementias (ADRD) diagnosis among AL
residents, and range anywhere from 40% to 72%.1-7 Esti-
mates derived from the National Survey of Residential Care
Facilities suggest that in 2010, 7 of 10 AL residents had
some form of cognitive impairment, with 19% exhibiting
severe cognitive impairment.3 Persons with ADRD residing
in AL represent a population with an increased risk of poor
outcomes. For example, persons with ADRD often have co-
occurring chronic illnesses, putting them at risk for higher
healthcare utilization.8 Further, individuals with ADRD are
not always able to advocate for themselves, making them
potentially vulnerable to abuse.9 Given the current size of
the AL industry and the large population of residents with
ADRD, more information is needed about the care pro-
vided to individuals with dementia residing in AL.
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The development and growth of the AL industry has
occurred largely without the influence of federal regulation.
The lack of federal regulation is mainly a result of the
funding structure of AL: in 2016, 84% of residents paid
privately for their care.1 With minimal federal oversight,
state regulations dictate requirements for licensure and
monitoring of AL. Previous work suggests that states vary
widely in their regulations specific to the care of AL resi-
dents with ADRD10-14 and their enforcement practices.15
Regulation has also increased and diversified over time: in
2000, 28 states had at least one regulatory requirement for
providing care to residents with ADRD in AL,16 and by
2014, that number had increased to 49 states.10 Given the
differences across states in what is considered AL and the
regulations related to caring for residents with ADRD (eg,
staffing requirements, level of care permitted), it is impor-
tant to examine state variation in the presence of AL resi-
dents with ADRD and their care experiences because
regulations likely shape providers’ behaviors and ultimately
residents’ outcomes.
The objectives of this study are to describe the state
variability in the prevalence of ADRD among AL residents
and their healthcare utilization. We use national Medicare
claims data to characterize the sociodemographic and
health characteristics of a cohort of Medicare beneficiaries
with ADRD who reside in larger (25+ bed) AL settings and
compare them with Medicare beneficiaries with ADRD liv-
ing in the community and nursing homes (NHs). In addi-
tion, we present cross-sectional state variability in the
prevalence of ADRD among a cohort of AL residents and
their rates of NH admission and acute care hospitalization,
and compare these rates with the population of community-
dwelling Medicare beneficiaries with ADRD.
METHODS
Data
Information on AL communities comes from a national cen-
sus we compiled from individual state licensing agencies. We
reviewed state websites and contacted state agents for infor-
mation on licensed AL/residential care settings in each state.
Licensing agencies provided information, at a minimum, on
the license type, address, and capacity. Following past work,
we only include AL residences licensed to serve a population
of older adults and with capacities for 25+ residents.1,17-20
Although larger AL communities (25+ beds) made up
approximately 39.2% of AL communities in 2016, they
comprised 84.1% of all licensed beds nationally.1 Therefore,
residential care settings with fewer than 25 beds, which rep-
resent more than 60% of licensed care settings but only
15.9% of residents, were not included in our analyses.
The Medicare Master Beneficiary Summary File (MBSF)
was used to obtain beneficiaries’ age, race, sex, reason for
Medicare entitlement, Medicaid eligibility, and date of
death. The Chronic Conditions Warehouse (CCW) segment
of the MBSF was used to identify beneficiaries’ chronic con-
ditions including ADRD (see Supplementary Material for
additional details). The MBSF was linked to a ZIP Code His-
tory File to obtain beneficiaries’ residential ZIP Codes.
To identify Medicare beneficiaries in AL, we updated a
previously published methodology relying on the 9-digit
ZIP Code reported in the MBSF1 (see Supplemental Mate-
rial for additional details) and created a finder file of
52,493 validated 9-digit ZIP Codes associated with 11,916
ALs (many large AL campuses have more than one 9-digit
ZIP Code). Using this finder file, we searched beneficiaries’
residential ZIP Codes to identify Medicare beneficiaries
residing in large AL settings with a validated 9-digit ZIP
Code pertaining to an AL on December 31, 2016.
To identify our cohorts of community-dwelling and
NH residents, we combined Medicare claims with the Mini-
mum Data Set and Home Health Outcome and Assessment
Information Set assessments to form a Residential History
File (RHF) that identifies a person’s location of care and
healthcare utilization on each day within a calendar year.21
Sample
We identified 439,272 Medicare beneficiaries with a ZIP
Code pertaining to an AL in the 48 contiguous states who
were not in any other healthcare setting on December
31, 2016. Because utilization and claims data are not avail-
able for Medicare Advantage (MA) beneficiaries, we excluded
AL residents with any MA coverage during calendar years
2016 and 2017, resulting in 293,336 beneficiaries enrolled in
traditional Medicare residing in AL on December 31, 2016.
We used the CCW segment of the MBSF to identify residents
with ADRD. This resulted in a sample of 88,867 (30.3%)
beneficiaries enrolled in traditional Medicare with an ADRD
diagnosis residing in AL on December 31, 2016.
To compare our sample of AL residents with ADRD
with other populations, we identified the population of
Medicare beneficiaries with an ADRD diagnosis residing in
the community (ie, were not in AL, an inpatient setting, or
an NH) on December 31, 2016, and without any MA enroll-
ment during 2016 and 2017 (n = 2,074,420). We also identi-
fied the population of beneficiaries enrolled in traditional
Medicare in 2016 and 2017 with an ADRD diagnosis who
were in an NH on December 31, 2016 (n = 602,521).
Measures
The RHF was used to create the following outcomes for each
of the study cohorts: any NH admission (both post-acute
and long-stay) and any inpatient acute hospitalization during
2017. Inpatient acute hospitalization was specified for NH
residents as an inpatient admission while an NH resident.
For AL and community residents, inpatient admissions were
included if they occurred while in AL or the community
(ie, hospitalizations from an NH were not included).
Analyses
We conducted descriptive analyses documenting the differ-
ences in demographic and health characteristics among
Medicare beneficiaries with an ADRD diagnosis who
resided in AL with those residing in the community or an
NH. We then calculated the percentage of AL residents with
ADRD in each of the 48 states. Next, we estimated separate
logistic regression models for each outcome measure
(ie, NH admission and hospitalization) for AL and
community-dwelling residents with ADRD. The models
adjusted for age group (≤64, 65-74, 75-84, 85-94, and ≥95
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y), sex, race,22 dual eligibility (ie, Medicare and Medicaid)
status in December 2016, and the presence and number
(<2, 2-3, 4-5, and ≥6) of the following chronic conditions:
anemia, atrial fibrillation, cancer, chronic kidney disease,
chronic obstructive pulmonary disease, depression, diabetes,
heart failure, hyperlipidemia, hypertension, ischemic heart
disease, and stroke.
We calculated the risk-adjusted rates of each outcome,
by state, as the ratio of observed events over expected
events in each state, multiplied by the national rate. The
risk-adjusted data were plotted to compare the rates of the
outcomes in AL vs the community. The bootstrap
resampling method was performed to estimate the 95%
confidence intervals (CIs) of adjusted rates, and two-sample
t tests were used to compare adjusted group means. All ana-
lyses were approved by the Brown University institutional
review board and conducted with SAS v.9.4 (SAS Institute,
Cary, NC) and Stata v.15.1 (StataCorp 2017, College Sta-
tion, TX). Additional information about the data and
methods used for these analyses can be found in the Brown
University Digital Repository (https://repository.library.
brown.edu/studio/item/bdr:1078482/).
RESULTS
A total of 88,867 (30.3%) beneficiaries enrolled in traditional
Medicare residing in AL had a diagnosis of ADRD, compared
with 6.1% in the community and 72.7% in NHs (Table 1).
Table 1. Demographic and Health Characteristics of Assisted Living Residents with a Diagnosis of Alzheimer’s Dis-
ease and Related Dementias Compared with Community-Dwelling and Nursing Home Residents
Assisted living Community Nursing home
N = 88,867 (30.3%) N = 2,074,420 (6.1%) N = 602,521 (72.7%)
Age groups,a y, n (%)
<65 2,925 (3.3) 130,588 (6.3) 34,138 (5.7)
65-74 7,587 (8.5) 362,158 (17.5) 83,208 (13.8)
75-84 19,604 (22.1) 727,822 (35.1) 169,192 (28.1)
85-94 45,869 (51.6) 726,491 (35) 243,909 (40.5)
95+ 12,882 (14.5) 127,360 (6.1) 72,074 (12)
Sex, n (%)
Male 27,107 (30.5) 797,248 (38.4) 187,800 (31.2)
Female 61,760 (69.5) 1,277,171 (61.6) 414,721 (68.8)
Race, n (%)
White 81,624 (91.9) 1,642,568 (79.2) 478,472 (79.4)
Black 3,668 (4.1) 199,346 (9.6) 74,269 (12.3)
Hispanic 1,913 (2.2) 137,109 (6.6) 31,667 (5.3)
Other 1,662 (1.9) 95,396 (4.6) 18,113 (3)
Dual eligible,a n (%) 18,503 (20.8) 487,601 (23.5) 451,920 (75)
Chronic conditions,a n (%)
Anemia 39,457 (44.4) 791,298 (38.2) 342,002 (56.8)
Atrial fibrillation 16,474 (18.5) 300,995 (14.5) 106,911 (17.7)
Cancer 8,833 (9.9) 205,119 (9.9) 47,194 (7.8)
Chronic kidney disease 34,101 (38.4) 774,811 (37.4) 274,375 (45.5)
Chronic obstructive pulmonary disease 17,909 (20.2) 384,770 (18.6) 149,652 (24.8)
Depression 38,697 (43.5) 698,182 (33.7) 339,951 (56.4)
Diabetes 27,588 (31.0) 733,149 (35.3) 256,216 (42.5)
Heart failure 29,525 (33.2) 569,210 (27.4) 250,358 (41.6)
Hyperlipidemia 46,799 (52.7) 1,134,061 (54.7) 295,509 (49.1)
Hypertension 71,137 (80.1) 1,555,130 (75) 508,506 (84.4)
Ischemic heart disease 40,351 (45.4) 897,237 (43.3) 289,819 (48.1)
Stroke 8,718 (9.8) 208,144 (10) 95,772 (15.9)
2+ chronic conditions,a n (%) 77,354 (87) 1,708,310 (82.4) 559,050 (92.8)
4+ chronic conditions,a n (%) 53,118 (59.8) 1,128,755 (54.4) 421,013 (69.9)
6+ chronic conditions,a n (%)1 27,277 (30.7) 567,905 (27.4) 240,041 (39.8)
Healthcare utilization,b n (%)
Any nursing admissionc 21,151 (23.8) 342,190 (16.5) N/A
Any hospitalizationc 33,457 (37.6) 697,968 (33.6) 174,323 (28.9)
No. of hospitalizations,d mean (standard deviation) 1.48 (.92) 1.58 (1.11) 1.55 (1.02)
Mortality rate,b n (%) 17,491 (19.7) 303,891 (14.7) 187,350 (31.1)
aAs of December 31, 2016.
bDuring 2017.
cNursing home admission and/or hospitalization occurred while in that setting.
dNumber of hospitalizations that occurred while in that setting, among those with any hospitalization during the year. Data come from the 2016 and 2017
Medicare Master Beneficiary Summary File, chronic conditions, and Residential History File.
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Our national cohort of beneficiaries with ADRD residing in
AL were more likely to be older, female, and white than
Medicare beneficiaries with a diagnosis of ADRD living in
the community or NH. AL residents had more diagnosed
chronic conditions than the community-dwelling population
with ADRD but fewer than NH residents with ADRD. In
addition, AL residents with ADRD had rates of hospitaliza-
tion higher than community-dwelling and NH residents with
ADRD (37.6% vs 33.6% and 28.9%, respectively).
Among our cohort of AL residents, states varied in their
unadjusted percentage of residents with an ADRD diagnosis,
from 23.6% in Minnesota to 47.2% in North Carolina
(Figure 1 and Supplementary Table S1). In 2017, a total of
21,151 (23.8%) AL residents with an ADRD diagnosis were
admitted to an NH during the year compared with 16.5% of
community-dwelling beneficiaries with ADRD. The adjusted
percentage of AL residents with an NH admission varied by
state, ranging from 13.7% (95% CI = 9.7-18.7) in NewMex-
ico to 34.9% (95% CI = 29-40.5) in North Dakota. Figure 2
shows that the rate of NH admission among AL residents is
higher than in the community, but that state-level rates are
strongly correlated (r = .74). With few exceptions, states
whose community rates of NH admission were above/below
the median also had higher/lower NH admission among AL
residents. Delaware, North Dakota, and Connecticut had the
greatest absolute difference in the rate of NH admission
Figure 1. Geographic variability in the share of beneficiaries enrolled in traditional Medicare residing in assisted living with a diag-
nosis of Alzheimer’s disease and related dementias (ADRD) (2016). Data come from the 2016 Medicare Master Beneficiary Sum-
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Figure 2. Adjusted* percentage of Medicare beneficiaries with Alzheimer’s disease and related dementias (ADRD) with a nursing
home admission in 2017. *Percentage adjusted for age, race, sex, dual eligibility, chronic conditions, and the number of chronic
conditions. Data come from the 2016 and 2017 Medicare Master Beneficiary Summary File and the Residential History File.
Dashed lines indicate median values. [Color figure can be viewed at wileyonlinelibrary.com]
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between AL and community-dwelling beneficiaries with
ADRD, with a more than 12 percentage point higher rate in
AL than the community (Figure 2 and Supplementary
Table S2). The NH admission rate in the community was only
nominally higher but not significantly different from AL (<2
percentage point difference) in two states: New Hampshire
and Vermont.
In our cohort, 33,457 (37.6%) AL residents with ADRD
were hospitalized during the year compared with 33.6% of
community-dwelling beneficiaries with ADRD. The adjusted
percentage of AL residents with ADRD hospitalized within
the year varied by state and ranged from 29.1% (95% CI =
23.4-35.9) in New Mexico to 44.8% (95% CI = 40.7-49.2)
in Arkansas (Figure 3). When comparing the adjusted rates
of hospitalization in AL vs the community, Arkansas, Rhode
Island, Georgia, and Nevada had the greatest absolute differ-
ence (>7 percentage points) in the adjusted rate of hospitali-
zation (Supplementary Table S3). The rate of hospitalization
in the community was nominally higher (<3 percentage
points) but not significantly different from AL in seven states:
New Hampshire, Vermont, New Mexico, Maryland, South
Dakota, Maine, and Connecticut.
DISCUSSION
This analysis is the first to compare the sociodemographic and
health characteristics of Medicare beneficiaries with ADRD
who reside in AL with those living in the community and
NHs. We found that several measures of health of our
national cohort of AL residents with ADRD fell in between
ADRD patients in the community and those in NHs. Among
AL residents, we observed state variation in the presence of
ADRD, suggesting potential differences in access to AL for
patients with ADRD. This article is also the first to examine
the healthcare utilization of AL residents with ADRD by state.
We found that the rates of NH admission and hospitalization
among our cohort of AL residents varied dramatically across
the country, and, on average, they were higher than
community-dwelling beneficiaries with ADRD. In the follow-
ing paragraphs, we describe some of the potential mechanisms
behind the state variability we observed in this study.
Our findings suggest that states vary in the proportion
of AL residents with an ADRD diagnosis. This interstate
variability could be a function of market forces, regulatory
requirements, and AL provider behavior. For example, it
may be that there are geographic differences in the clinical
diagnosis of ADRD, as was previously observed across
states and rural/urban locations.23,24 The variation in the
prevalence of ADRD in AL could also be a function of dif-
ferences in states’ long-term services and supports available
to care for individuals with ADRD.25
In addition to availability, states may vary in how they
assist residents in financing AL. Given that close to one-
quarter of all patients with ADRD in the community are
enrolled in Medicaid,26 the availability of public subsidies
(eg, Medicaid benefits for services provided in AL and gen-
erosity of state supplements to pay for care in AL10,27) also
may be driving the state variability in AL residents with
ADRD. Notably, Pennsylvania, a state with one of the low-
est prevalence rates of ADRD among AL residents (24.9%),
despite being home to one of the oldest populations in the
country,28 is one of a handful that does not provide services
funded by Medicaid to residents in AL.
The variation in states’ regulations pertaining to demen-
tia care may also be associated with variation in the preva-
lence of ADRD in AL across states. For example, some states
require dementia-specific preadmission screening (14 states),
consumer disclosure (33 states), and building design to
accommodate the needs of residents with ADRD
(29 states),11 and these differences likely impact AL providers’
willingness to accept residents with an ADRD diagnosis.
Future research is needed to better understand the market
and regulatory factors that may contribute to the state vari-
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Adjusted Percent with Any Hospitalization Among Assisted-Living Residents with ADRD
Figure 3. Adjusted* percentage of Medicare beneficiaries with Alzheimer’s disease and related dementias (ADRD) with a hospitaliza-
tion in 2017. *Percentage adjusted for age, race, sex, dual eligibility, chronic conditions, and the number of chronic conditions. Hos-
pitalizations occurred before moving to a nursing home. Data come from the 2016 and 2017 Medicare Master Beneficiary Summary
File and the Residential History File. Dashed lines indicate median values. [Color figure can be viewed at wileyonlinelibrary.com]
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We also observed significant state variation in the rates
of using NH care among AL residents with ADRD. Two
types of factors may contribute to variation in NH admis-
sion rates: those that affect both community and AL resi-
dents, and those specific to AL. The mechanisms driving the
differences in NH admission in both settings, therefore lead-
ing to strong correlation between community and AL rates,
are likely related to potential factors contributing to differ-
ential access, as listed earlier (eg, market factors). For exam-
ple, the number of NH beds per capita vary across the
country, as does post-acute skilled nursing facility utiliza-
tion.29,30 It may be the case that in states with less robust
Medicaid support for home- and community-based services,
individuals with ADRD living in the community may be left
with few care alternatives to NHs.
The variation in NH placement among AL residents
across states may also reflect differences in Medicaid policies:
states without Medicaid waivers or state plans allowing for
services to be provided in AL may result in residents spend-
ing down their assets, requiring relocation to an NH or other
setting that accepts Medicaid reimbursement. State regula-
tions related to retention or move-out requirements may
affect the case mix within AL,31 thereby potentially driving
the differences in NH admission across states.
In North Dakota, the state with the highest NH admis-
sion rate, AL settings may not retain residents who require
more than intermittent nursing care unless the resident
requires and elects to receive end-of-life care from a
Medicare-certified hospice agency and the AL is licensed to
provide end-of-life care (NDAC 33-03-24.1).32 This policy
might result in transfers of residents with ADRD who have
nursing care needs that are not deemed as life limiting.
State-specific dementia care rules might also influence
the number of individuals with ADRD who are able to
maintain residence in AL as their disease progresses. For
example, Vermont, a state with a higher NH admission rate
in the community than AL, has a policy that residents “will
be permitted to age in place” (CVR 13-110-007.6.5)33 pro-
vided that their mobility, ambulation, and transfer needs
can be met by one staff person, cognitive impairment is at a
moderate or lesser degree of severity, and behavioral symp-
toms consistently respond to appropriate intervention.
Other regulatory requirements, such as staffing, admis-
sion criteria, care processes, and tolerance for aging in place,
might also explain the differences in NH admission observed
among states. Our findings set the stage for future work
examining the relative contribution of these market, financ-
ing, and regulatory factors on the state variations observed in
this study.
Nationally, our cohort of AL residents with ADRD
had higher rates of hospitalization than community-
dwelling and NH residents, and the differences between AL
and community rates varied by state. These rates might
reflect differences in quality of care provided in AL, state
requirements for level of care to be provided, or underlying
patient need. It is impossible to draw conclusions about the
quality of care provided in AL because systematic
unmeasured aspects of health, such as the level of functional
and cognitive impairment, could contribute to AL residents’
differences in hospitalization rates. Additional work exam-
ining hospitalizations conditioned on underlying patient
need is important and required to better understand the
quality of care provided to residents with ADRD in AL
compared with the community and NHs.
As it relates to state regulations for dementia care
requirements, of the four states with the greatest differences
in AL and community rates of hospitalization, three
(Arkansas, Rhode Island, and Nevada) require dementia
care units to be licensed. However, of the seven states with
lower rates of hospitalization in AL, only Connecticut
requires dementia care units to be licensed.11 It is possible
that states with more stringent rules for dementia care set-
tings have provisions that result in differential rates of hos-
pitalization or that they admit residents with differing levels
of need. However, documentation of state variation in
dementia care requirements for AL is limited.
One regulatory review found that only seven states spec-
ify minimum staffing levels or ratios in dementia care units;
13 states specified administrator training requirements, with
the total hours of training ranging from 7 to 120 hours in
the first year, and 14 states required a preadmission assess-
ment of dementia care needs.11 Given the previous link
between nurse staffing levels, staffing mix, and AL residents’
outcomes,34,35 it is possible that state staffing requirements
may also be associated with differences in rates of hospitali-
zation. Future research is needed to assess systematically
whether and how differences in states’ requirements for
dementia care, particularly staffing levels and mix, affect
hospitalization of AL residents with ADRD.
Differences among states in healthcare utilization of
their AL residents may be a function not only of states’ reg-
ulations but also how those regulations are monitored and
enforced. Although the relationship between enforcement of
regulations and resident outcomes has not been explored in
the context of AL, the link between oversight and quality of
care in NHs has been well documented. For example,
implementation of the Nursing Home Reform Act care
standards and surveillance system was tied to reductions in
chemical restraints and improved resident quality of care.36
Following the nationwide implementation of the National
Partnership to Improve Dementia Care in Nursing Homes,
one study37 found state agencies supporting frequent facility
monitoring had reduced rates of inappropriate antipsy-
chotic prescribing. Additional work to understand the rela-
tionship between how states enforce regulations and
residents’ outcomes is an area of important study.
Limitations
This analysis has limitations. First, we present a cross
section of data and report on the resident composition and
healthcare utilization in 2017; therefore, we are unable to
draw any causal conclusions. As such, we do not formally
measure the impact of market factors, regulations, or enforce-
ment that may be attributable to the geographic variation
observed.
Second, our ascertainment of ADRD relies on a diagno-
sis in Medicare claims. Therefore, we may be under-
estimating the prevalence of residents with ADRD4 and are
unable to identify the prevalence of ADRD among MA
enrollees. Given the varying diagnosing patterns23,24 and
MA penetration rate across states,38 this may bias our esti-
mates of ADRD prevalence in these settings. However,
it does not appear that AL prevalence rates across
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states track those among community-dwelling older adults
(Supplementary Table S1).
Third, our methodology depends on identifying resi-
dents in larger AL settings (25+ beds), limiting its generaliz-
ability to smaller settings. Data from the National Study of
Long-Term Care Providers (NSLTCP) suggests that the per-
centage of residents with ADRD decreases with increasing
AL size, from 51% of residents in AL settings with 4 to
25 beds, to 44% with 26 to 50 beds, to 39% in the largest
AL settings (50+ beds). Understandably, our study had
lower rates of ADRD than previously published findings
from the 2016 NSLTCP.39 In addition, relying on 9-digit
ZIP Codes to identify AL residents means that we are only
able to identify residents who changed their addresses, and
we may be including independent living residents on the
same campus.
Finally, this study was designed and carried out using
the state as the primary unit of analysis. However, most
states provide two or more types of licensed care that falls
under the umbrella of AL, and requirements for licensed
settings within a state can vary. Additional investigation is
needed to better understand the within-state variability that
is likely to exist in resident characteristics and outcomes.
Despite these limitations, our study presents the first insight
into the state variability in the prevalence of ADRD and
residents’ healthcare utilization.
In conclusion, for several decades, AL has been pre-
ferred by older adults who need assistance with personal
care and health-related needs. As this and other recent stud-
ies have indicated,1-7 AL serves significant numbers of older
adults with ADRD. The state variation in the percentage of
residents with ADRD diagnoses, and the variation in their
health service utilization, suggest unequal access to AL, dif-
ferences in care processes, as well as possible underlying
variability in the population of beneficiaries with ADRD
residing in AL. The reasons for such differences are as yet
unknown, although market forces, regulatory requirements,
and enforcement may play important roles. Our findings
suggest that clinicians caring for residents in these settings
likely practice under varying constraints. These findings
also point to the importance of clinicians’ familiarity with
state and specific AL communities’ requirements for care.
Ultimately, these findings call for further work to better
understand the factors that might be driving the variations
observed in this study.
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